Russian-made medicines account for up to 72% of public procurement in Russia

12 March 2018

GMP News

In 2017, the public procurement of medicines decreased slightly (with stronger decline in physical rather than monetary terms) and amounted to 340 billion rubles and 0.88 billion packages. These figures were reported in the review of public procurement of medicines for 2017.

Prescription drugs accounted for about 98% of procurement in monetary terms and 90% in physical terms. Russian-made medicines accounted to 72% of procurement in terms of packages or 45% in monetary terms. More than 80% of medicinal products in the public segment (both in monetary and physical terms) are included in the List of Vital and Essential Drugs.

SG Biotech was the most prominent among the manufacturers of drugs shipped to state health facilities following the public procurement. This joint venture between Generium, a Russian biotech company, and Shire, an Irish pharmaceutical company, was registered in Russia in 2016 to supply drugs for hemophilia included in the list of high-cost nosologies. 2017 was a successful year for SG Biotech, as it jumped from 16th to the 9th position in the ranking. Among Top 20 companies, the most significant decline was reported for Celgene, which dropped by 8 positions in the ranking. This is associated with the price reduction for lenalidomide, its flagship INN, caused by the emergence of competitors in the auctions.

Previous publication Next publication

Media Center

  • 19 September 2018

    Russia approves new state strategy for pharmaceutical industry

    A new state strategy for the development of the domestic pharmaceutical industry, known as "Strategy for the development of the pharmaceutical industry of Russia until 2030," has been recently approved by the Russian Ministry of Industry and Trade, with the aim to bring the Russian pharmaceutical production to a new level.

  • 18 September 2018

    The Ministry of Health of the Russian Federation improves patent protection law

    The Ministry of Health of Russia has published a notification on the development of amendments to Federal Law No. 61 of 12.04.2010 “On circulation of medicinal products”, designed to synchronize it with regulatory acts of the Eurasian Economic Union. The procedure for registration of the medicinal product will be corrected.

  • 17 September 2018

    GlobalData published new report on the Top 25 pharma companies

    The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company.

  • 14 September 2018

    US scientists conduct clinical trial of influenza vaccine with imiquimod

    A Phase 1 clinical trial examining whether a topical cream can enhance the immune response conferred by a “pre-pandemic” influenza vaccine is underway at Baylor College of Medicine in Houston (USA). Investigators are evaluating whether imiquimod cream, which is commonly used to treat genital warts and certain skin cancers, can boost the body’s immune response to an H5N1 influenza vaccine. The trial is enrolling 50 healthy adults ages 18-50 years. 

Read more